
Europe Biobanking Market Report and Forecast 2024-2032
Description
Europe Biobanking Market Report and Forecast 2024-2032
Europe Biobanking Market Report and Forecast 2024-2032
Europe Biobanking Market Outlook
The global biobanking market size was valued at USD 72.1 billion in 2023, with Europe holding a significant market share. The market is driven by increasing investment in biomedical research. It is expected to grow at a CAGR of 6.60% during the forecast period of 2024-2032, with the values likely to attain USD 131.1 billion by 2032.
Key Takeaways
- Major funding initiatives are pivotal in establishing and expanding the biobank resources and are likely to boost the market share. In May 2023 , the United Kingdom Biobank was reported to receive EUR 127.6 million in funding from the UK Research and Innovation (UKRI) to support its move to a new facility at Bruntwood SciTech’s Manchester Science Park.
- One of the significant Europe biobanking market trends is the rise in workflow automation in biobanking procedures to increase throughput as well as enable sample tracking and error reduction. For instance, in February 2023 , a team of German researchers employed a robotic system to automate the isolation of peripheral blood mononuclear cells (PBMC) for biobanking samples.
- The International Agency for Research on Cancer (IARC) stated that the number of new cancer cases is projected to rise by 22.5% over the next two decades in Europe. Since biobanks play a crucial role in supporting research aimed at developing innovative treatments, the market size is likely to increase in the coming years.
A biobank can be defined as a repository that collects, processes, stores, and distributes biological materials such as tissues, blood, and DNA, among others. In Europe, these biological samples and associated health data are increasingly utilized for medical research and diagnostic purposes. With the rising emphasis on translating scientific research into clinical applications coupled with the growing impetus towards the development of personalized medicine, the Europe biobanking market demand is expected to witness a surge in the forecast period.
The market is greatly influenced by substantial investments from government bodies and private organizations across Europe. In May 2023, the United Kingdom Biobank (large-scale biomedical database) was reported to receive EUR 127.6 million in funding from the national funding agency UK Research and Innovation (UKRI) to support its move to a new facility at Bruntwood SciTech’s Manchester Science Park. With improved technologies and capacity at the purpose-built facility, the UK Biobank is expected to drive innovation in healthcare research and open new opportunities for collaboration. Such major funding initiatives are pivotal in establishing and expanding the biobank resources and are likely to boost the Europe biobanking market growth.
One of the significant market trends is the rise in workflow automation in biobanking to increase output as well as offer sample tracking and error reduction. For instance, in February 2023 , a team of German researchers employed a robotic system to automate the isolation of peripheral blood mononuclear cells (PBMC) for biobanking samples. The novel robotic system exhibited equivalent cell yield, composition, and viability, as compared to manual processing, revealing its potential as a robust tool for collecting high-quality clinical samples for biobanking in the hematology and immunology field. The integration of such technologies in the biobanking procedures is likely to ensure high-quality samples and data, thereby elevating the Europe biobanking market share.
The market is also influenced by the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases, among others, in the region. According to the International Agency for Research on Cancer (IARC), the number of new cancer cases is projected to rise by 22.5% over the next two decades in Europe. As biobanks play a vital role in supporting research aimed at understanding the cause of disease and developing innovative treatments, the market value is likely to increase in the coming years.
Europe Biobanking Market Segmentation
Market Breakup by Product and Service
- Equipment
- Consumables
- Service
- Software
- Regenerative Medicine
- Life Science Research
- Clinical Research
- Blood Tissue
- Nucleic Acids
- Cell Lines
- Academic Institutions
- Pharma and Biotech Companies
- United Kingdom
- Germany
- France
- Italy
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- QIAGEN N.V.
- Merck KGaA
- Tecan Trading AG
- Greiner Holding AG
- Micronic
- BioKryo
- SPT Labtech
- ASKION GmbH
- Cell&Co BioServices
- CTIBiotech
FAQs
- What is the Europe biobanking market forecast outlook for 2024-2032?
- What are the major factors aiding the Europe biobanking market demand?
- What are the major Europe biobanking market trends?
- What is the market segmentation based on the product and services?
- What is the market breakup by sample type?
- What are the major end users of biobanking?
- What are the applications of biobanking?
- What is the market segmentation by countries?
- Who are the key players involved in the Europe biobanking market?
Meta description
Europe biobanking market is poised for growth, driven by the expansion of the global market which was valued at USD 72.1 billion in 2023, and is projected to grow at a CAGR of 6.89% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Europe Biobanking Market Overview
- 3.1 Europe Biobanking Market Historical Value (2017-2023)
- 3.2 Europe Biobanking Market Forecast Value (2024-2032)
- 4 Europe Biobanking Market Landscape*
- 4.1 Europe Biobanking: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Europe Biobanking: Product Landscape
- 4.2.1 Analysis by Product and Service
- 4.2.2 Analysis by Application
- 5 Europe Biobanking Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Europe Biobanking Market Segmentation (2017-2032)
- 6.1 Europe Biobanking Market (2017-2032) by Product and Service
- 6.1.1 Market Overview
- 6.1.2 Equipment
- 6.1.3 Consumables
- 6.1.4 Service
- 6.1.5 Software
- 6.2 Europe Biobanking Market (2017-2032) by Application
- 6.2.1 Market Overview
- 6.2.2 Regenerative Medicine
- 6.2.3 Life Science Research
- 6.2.4 Clinical Research
- 6.3 Europe Biobanking Market (2017-2032) by Sample Type
- 6.3.1 Market Overview
- 6.3.2 Blood Tissue
- 6.3.3 Nucleic Acids
- 6.3.4 Cell Lines
- 6.4 Europe Biobanking Market (2017-2032) by End User
- 6.4.1 Market Overview
- 6.4.2 Academic Institutions
- 6.4.3 Pharma and Biotech Companies
- 6.5 Europe Biobanking Market (2017-2032) by Country
- 6.5.1 Market Overview
- 6.5.2 United Kingdom
- 6.5.3 Germany
- 6.5.4 France
- 6.5.5 Italy
- 7 United Kingdom Biobanking Market (2017-2032)
- 7.1 United Kingdom Biobanking Market (2017-2032) by Product and Service
- 7.1.1 Market Overview
- 7.1.2 Equipment
- 7.1.3 Consumables
- 7.1.4 Service
- 7.1.5 Software
- 7.2 United Kingdom Biobanking Market (2017-2032) by Application
- 7.2.1 Market Overview
- 7.2.2 Regenerative Medicine
- 7.2.3 Life Science Research
- 7.2.4 Clinical Research
- 7.3 United Kingdom Biobanking Market (2017-2032) by Sample Type
- 7.3.1 Market Overview
- 7.3.2 Blood Tissue
- 7.3.3 Nucleic Acids
- 7.3.4 Cell Lines
- 7.4 United Kingdom Biobanking Market (2017-2032) by End User
- 7.4.1 Market Overview
- 7.4.2 Academic Institutions
- 7.4.3 Pharma and Biotech Companies
- 8 Germany Biobanking Market (2017-2032)
- 8.1 Germany Biobanking Market (2017-2032) by Product and Service
- 8.1.1 Market Overview
- 8.1.2 Equipment
- 8.1.3 Consumables
- 8.1.4 Service
- 8.1.5 Software
- 8.2 Germany Biobanking Market (2017-2032) by Application
- 8.2.1 Market Overview
- 8.2.2 Regenerative Medicine
- 8.2.3 Life Science Research
- 8.2.4 Clinical Research
- 8.3 Germany Biobanking Market (2017-2032) by Sample Type
- 8.3.1 Market Overview
- 8.3.2 Blood Tissue
- 8.3.3 Nucleic Acids
- 8.3.4 Cell Lines
- 8.4 Germany Biobanking Market (2017-2032) by End User
- 8.4.1 Market Overview
- 8.4.2 Academic Institutions
- 8.4.3 Pharma and Biotech Companies
- 9 France Biobanking Market (2017-2032)
- 9.1 France Biobanking Market (2017-2032) by Product and Service
- 9.1.1 Market Overview
- 9.1.2 Equipment
- 9.1.3 Consumables
- 9.1.4 Service
- 9.1.5 Software
- 9.2 France Biobanking Market (2017-2032) by Application
- 9.2.1 Market Overview
- 9.2.2 Regenerative Medicine
- 9.2.3 Life Science Research
- 9.2.4 Clinical Research
- 9.3 France Biobanking Market (2017-2032) by Sample Type
- 9.3.1 Market Overview
- 9.3.2 Blood Tissue
- 9.3.3 Nucleic Acids
- 9.3.4 Cell Lines
- 9.4 France Biobanking Market (2017-2032) by End User
- 9.4.1 Market Overview
- 9.4.2 Academic Institutions
- 9.4.3 Pharma and Biotech Companies
- 10 Italy Biobanking Market (2017-2032)
- 10.1 Italy Biobanking Market (2017-2032) by Product and Service
- 10.1.1 Market Overview
- 10.1.2 Equipment
- 10.1.3 Consumables
- 10.1.4 Service
- 10.1.5 Software
- 10.2 Italy Biobanking Market (2017-2032) by Application
- 10.2.1 Market Overview
- 10.2.2 Regenerative Medicine
- 10.2.3 Life Science Research
- 10.2.4 Clinical Research
- 10.3 Italy Biobanking Market (2017-2032) by Sample Type
- 10.3.1 Market Overview
- 10.3.2 Blood Tissue
- 10.3.3 Nucleic Acids
- 10.3.4 Cell Lines
- 10.4 Italy Biobanking Market (2017-2032) by End User
- 10.4.1 Market Overview
- 10.4.2 Academic Institutions
- 10.4.3 Pharma and Biotech Companies
- 11 Regulatory Framework
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication Year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by Year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding and Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Market Share by Top 5 Companies
- 16.2 QIAGEN N.V.
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Mergers and Acquisitions
- 16.2.5 Certifications
- 16.3 Merck KGaA
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Mergers and Acquisitions
- 16.3.5 Certifications
- 16.4 Tecan Trading AG
- 16.4.1 Financial Analysis
- 16.4.2 Product Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Mergers and Acquisitions
- 16.4.5 Certifications
- 16.5 Greiner Holding AG
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Mergers and Acquisitions
- 16.5.5 Certifications
- 16.6 Micronic
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Mergers and Acquisitions
- 16.6.5 Certifications
- 16.7 BioKryo
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Mergers and Acquisitions
- 16.7.5 Certifications
- 16.8 SPT Labtech
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Mergers and Acquisitions
- 16.8.5 Certifications
- 16.9 ASKION GmbH
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Mergers and Acquisitions
- 16.9.5 Certifications
- 16.10 Cell&Co BioServices
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic
- 16.10.4 Mergers and Acquisitions
- 16.10.5 Certifications
- 16.11 CTIBiotech
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Mergers and Acquisitions
- 16.11.5 Certifications
- 17 Europe Biobanking Market – Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.